CTOR — Citius Oncology Balance Sheet
0.000.00%
- $178.88m
- $182.68m
Annual balance sheet for Citius Oncology, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2022 September 30th | 2023 September 30th | 2024 September 30th | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Cash and Equivalents | |||
Cash and Short Term Investments | 0 | 0 | 0 |
Total Inventory | |||
Prepaid Expenses | |||
Total Current Assets | 2.69 | 7.73 | 11 |
Net Intangible Assets | |||
Total Assets | 42.7 | 47.7 | 84.4 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 5.85 | 21 | 32.7 |
Long Term Debt | |||
Total Long Term Debt | |||
Total Debt | |||
Deferred Income Tax | |||
Total Other Liabilities | |||
Total Liabilities | 6.42 | 22.2 | 38.2 |
Non Redeemable Preferred Stock | |||
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Total Equity | 36.3 | 25.5 | 46.1 |
Total Liabilities & Shareholders' Equity | 42.7 | 47.7 | 84.4 |
Total Common Shares Outstanding |